A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function
Terminated · Phase 1 · NCT04241835
Conditions: Hepatic Impairment, Advanced Malignant Solid Tumor
At a glance
- Research payments reported, 2025
- $207,343
- U.S. investigators named
- 7
- Sites paid
- 7
- Planned or actual enrollment
- 18
About the trial
- Sponsor
- Epizyme, Inc. (with Sponsor GmbH)
- Tested
- Tazemetostat (drug)
- Dates
- Started 2020-01-15; completion 2025-03-12
- Results posted
- Not yet
This main aim of this trial will be to study the blood levels (known as pharmacokinetics) of the study drug tazemetostat. The pharmacokinetics of the study drug in participants with advanced solid tumors and moderate or severe hepatic (liver) impairment will be compared with participants with advanced malignancies and normal hepatic function. An advanced malignancy is a cancer that has recurred (come back) after prior treatment or hasn't controlled with treatment. The trial will also study the safety of the study drug in participants (how well it is tolerated).
From ClinicalTrials.gov, last updated 2026-04-16. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Epizyme, Inc. reported $207,343 in research payments for this study in 2025 (35 payments).
Products named: Tazverik
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Alexander Philipovskiy, M.D., PH.D Medical Oncology · Sanford, FL
- Devalingam Mahalingam, M.D. Medical Oncology · Chicago, IL
- Savitha Balaraman, MD Medical Oncology · Madison Heights, MI
- Sanjay Goel, MD Medical Oncology · New Brunswick, NJ
- Nashat Gabrail, M.D. Specialist · Canton, OH
- Reva Schneider Medical Oncology · Dallas, TX
- Mohamad A. Salkeni, M.D. Hematology & Oncology · Fairfax, VA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Rutgers the State University of New Jersey $108,469
- Virginia Cancer Specialists $46,601
- Sarah Cannon Cancer Institute at Hdh $16,750
- Mary Crowley Cancer Research $9,495
- Profound Research LLC $9,465
- Northwestern University $9,007
- Gabrail Cancer and Research Center $7,557
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.